Final Verdict: Research Comparison Feature Tirzepatide Retatrutide Receptor Targets GLP-1, GIP GLP-1, GIP, Glucagon Half-Life ~5 Days ~6 Days Max Published Weight Loss ~21% (72w) ~24% (48w) Liver Fat Reduction Moderate/High Extreme Primary Research Focus Glycemic Control Metabolic Reset / REE Future Outlook: Post-2025 Research Landscape As we look toward 2026 and beyond, the data from the Phase 3 TRIUMPH trials will likely solidify retatrutides position in the metabolic research hierarchy
The Cysterhood app is loaded with easy, PCOS-friendly, high-protein recipes to make your meals both nourishing and delicious
The placement of incisions in natural breast creases and around the areolar border helps camouflage scarring
Should marketing authorisation be granted, NICE would subsequently need to evaluate retatrutide for clinical and cost-effectiveness before it could be routinely commissioned on the NHS a process that typically follows initial regulatory approval
GLP-2 injection resulted in increase in crypt depth and villus height as well as significant reduction of proinflammatory markers such as IL-1, IFN-, and TNF- (Sigalet et al
